Abstract: Objective The aim of this study was to investigate the clinical efficacy of percutaneous cather drainage (PCD) under ultrasound (US) guidance with lauromacrogol replacement for sclerotherapy in patients with huge hepatic cysts. Methods A total of 73 patients with huge hepatic cysts were enrolled in our hospital between January 2018 and December 2020, and were randomly divided into control (n=36 and observation group (n=37). The patients in both groups underwent PCD under US guidance, and the patients in the control were given anhydrous ethanol for sclerotherapy, while those in the observation group were given lauromacrogol replacement for sclerotherapy. All patients were followed-up for 6 months after surgery. Serum C-reactive protein (CRP) and serum amyloid A (SAA) levels were detected by chemiluminescence, and serum cortisol (Cor) level was detected by magnetic particle chemiluminescence. Results At the end of 6 month followed-up, the total clinical effectiveness, the disappearance, or largely disappearance, of the cysts, in the observation group was 97.3%, significantly higher than 80.6%(P＜0.05) in the control; there were no significant differences respect to liver function tests between the two groups before and after the surgery (P＞0.05); one week after the operation, serum CRP, Cor and SAA levels in the observation group were (15.7±3.6)mg/L, (283.6±10.3)nmol/L and (13.5±2.4)ng/mL, significantly lower than [(21.1±4.5)mg/L, (312.3±10.7)nmol/L and (19.8±3.7)ng/mL, respectively, P＜0.05] in the control. Conclusion The clinical efficacy of PCD under US guidance with lauromacrogol replacement for sclerotherapy in dealing with patients with huge hepatic cysts is good, with little adverse reactions.

Key words: Hepatic cysts, Percutaneous cather drainage, Ultrasound guidance, Lauromacrogol sclerotherapy, Therapy